Investigating ways to overcome drug resistance in acute myeloid leukemia treatment
Official title: Targeting AMP Synthesis to Overcome Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Funded at Beckman Research Institute/city of Hope · NIH-11132538 · Data updated 2026-11-12
This study is looking at how older patients with acute myeloid leukemia (AML) can get better treatment by figuring out why some of them stop responding to a drug called venetoclax, and they hope to find new ways to make the treatment work better for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | March 10, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $734,435 |
| NIH project number | 1R01CA292893-01A1 |
| Project ID | NIH-11132538 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults aged 60 years and above who have been diagnosed with acute myeloid leukemia.
✕Less likely to help
Patients with acute myeloid leukemia who are younger than 60 years or those who do not have resistance to venetoclax may not benefit from this research.
What this research studies
This research focuses on improving treatment outcomes for older patients with acute myeloid leukemia (AML) by understanding how resistance to a specific drug, venetoclax, develops over time. The team will explore the molecular mechanisms behind this resistance, particularly the role of an enzyme called ADSS2 in AMP synthesis. By using advanced techniques like CRISPR/Cas9 and patient-derived models, they aim to identify new therapeutic strategies that could enhance the effectiveness of existing treatments. The ultimate goal is to develop a combination therapy that can better target resistant leukemia cells.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for older patients with acute myeloid leukemia, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results in targeting drug resistance in leukemia, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Li, Ling — Beckman Research Institute/city of Hope
- Study coordinator: Li, Ling
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.